284
Participants
Start Date
December 17, 2024
Primary Completion Date
April 28, 2025
Study Completion Date
May 29, 2025
Ribavirin
Ribavirin is an antiviral medication administered as part of the intervention arm. It will be provided orally in a dosage of 15 mg/kg body weight twice daily (BD) for a duration of 7 days. The drug has demonstrated efficacy in vitro and in vivo against RNA viruses, including dengue, through mechanisms such as inosine monophosphate inhibition and immunomodulation.
Standard Treatment
"The standard treatment for dengue fever includes supportive care measures aimed at managing symptoms and preventing complications. These measures typically involve:~Intravenous (IV) fluid therapy for rehydration and maintaining hemodynamic stability.~Platelet transfusion as needed, based on clinical assessment and platelet counts.~Antipyretics for fever management (excluding non-steroidal anti-inflammatory drugs to prevent bleeding risks).~Continuous monitoring of vital signs and blood parameters, including platelet counts and hematocrit levels.~No antiviral drugs or additional pharmacological interventions are included in the standard treatment protocol."
Lady Reading Hospital, Peshawar
Gandhara Medical Hospital, Peshawar
Medical Complex Swabi, Swābi
Kohat Institute of Medical Science, Kohat
Khyber Medical University Peshawar
OTHER